DISCUSSION
Depression is one of the most common psychiatric disorders, affecting almost 350 million people around the world. It often leads to severe chronic functional impairment due to its symptoms.7 Executive function, memory, attention, processing speed and psychomotor functions are the cognitive domains which usually get affected significantly.8 American psychiatric association and other numerous guidelines have recommended both psychotherapy as well as pharmacotherapy for the management of depressive disorders. Selective serotonin reuptake inhibitors (SSRIs) are the preferred choice of pharmacotherapy in depression.9
Paroxetine is a phenylpiperidine derivative, was prescribed to this patient 10 years back, and since then he has been taking it on a regular basis. Paroxetine is the most potent inhibitor in the class of SSRI, and is used in the treatment of multiple disorders like depression, anxiety, obsessive-compulsive disorders, post-traumatic stress disorder and panic disorders.1 While being very efficacious, SSRI are known to have an association with increased chances of developing hyponatremia. The major risk factors that contribute to this adverse effect are the advancing age and the concomitant use of diuretics.10 The incidence of developing hyponatremia with the use of SSRI is 1 out of 1600 cases.11 
Our patient was a 52 years old hypertensive male, who had been taking antidepressants along with antihypertensive drugs. Therefore, he was at an increased risk of developing electrolyte imbalance.